Core Viewpoint - The company has received approval from the National Medical Products Administration for its hydrochloride hydromorphone injection, indicating its capability to produce and sell this product in the domestic market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has obtained the drug registration certificate for hydrochloride hydromorphone injection [1] - The hydrochloride hydromorphone injection (1ml:2mg) is intended for patients requiring opioid analgesia [1] - The approval signifies that the product has passed the consistency evaluation, allowing the company to enter the domestic market for this medication [1] Group 2: Market Considerations - The sales of the drug may be influenced by industry policies, tender procurement, and market conditions, which introduces uncertainty [1]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), has received approval from the National Medical Products Administration for its Hydromorphone Hydrochloride Injection, marking a significant step in expanding its product line in the anesthetic and analgesic sector [1] Group 1: Product Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has been granted a drug registration certificate for Hydromorphone Hydrochloride Injection, with the certificate number 2025S03532 [1] - Hydromorphone, a semi-synthetic opioid, has been in clinical use since 1926 and is indicated for patients requiring opioid analgesia [1] Group 2: Market Impact - The approval signifies that the company is now qualified to produce and sell this product in the domestic market, enhancing its competitive edge [1] - The addition of Hydromorphone Hydrochloride Injection to the company's anesthetic and analgesic product line is expected to positively influence its future development [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600420 证券简称：国药现代 公告编号：2025-090 上海现代制药股份有限公司 关于全资子公司获得药品注册证书的公告 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团工 业有限公司（以下简称国药工业）收到国家药品监督管理局核准签发的盐酸氢吗 啡酮注射液《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 药品名称：盐酸氢吗啡酮注射液 证书编号：2025S03532 剂型：注射剂 规格：1ml:2mg 注册分类：化学药品 3 类 药品有效期：18 个月 申请事项：药品注册（境内生产） 药品批准文号：国药准字 H20256055 上市许可持有人：国药集团工业有限公司廊坊分公司 二、药品研发及市场情况 氢吗啡酮（Hydromorphone）又名二氢吗啡酮或双氢吗啡酮，是一种半合成 的阿片类生物碱，1926 年投入临床应用。盐酸氢吗啡酮注射液适用于需使用阿 片类药物镇痛的患者。 根据米内网数据库显示，盐酸氢吗啡酮注射液近三年在全国公立医疗机构销 售 ...

Core Viewpoint - The announcement highlights that China National Pharmaceutical Group Modern (国药现代) has received approval from the National Medical Products Administration for the registration of hydromorphone hydrochloride injection, which is intended for patients requiring opioid analgesia [1] Company Summary - China National Pharmaceutical Group Modern's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., has successfully obtained the drug registration certificate for hydromorphone hydrochloride injection [1] - The approved drug is specifically designed for patients who need opioid medications for pain relief [1]

Core Viewpoint - The announcement from Guoyao Modern indicates the election of Wang Xiangfen as the employee representative director for the ninth board of directors during the fourth employee representative conference on November 20, 2025 [2] Group 1 - Guoyao Modern will hold the fourth employee representative conference on November 20, 2025 [2] - Wang Xiangfen has been elected as the employee representative director for the ninth board of directors [2]

证券代码：600420 证券简称：国药现代 公告编号：2025-089 上海现代制药股份有限公司 关于选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海现代制药股份有限公司（以下简称公司）于 2025 年 6 月 26 日召开 2024 年年度股东大会，审议通过了《关于修订<公司章程>暨取消监事会并废止相关 议事规则的议案》，依据修订后的《公司章程》，公司董事会由 9 名董事组成， 其中包括 1 名职工代表董事，职工代表董事由公司职工代表大会、职工大会或者 其他形式民主选举产生。 公司于 2025 年 11 月 20 日召开第四届职工代表大会第五次会议，经与会职 工代表审议，同意选举王香芬女士（简历附后）为公司第九届董事会职工代表董 事。王香芬女士与经公司股东会选举产生的第九届董事会非职工代表董事共同组 成公司第九届董事会，任期自第九届董事会正式履职之日起，至第九届董事会任 期届满之日止。 王香芬女士担任公司职工董事后，公司董事会中兼任公司高级管理人员职务 的董事以及由职工代表担任的董事人数总计未超过公司 ...

Core Viewpoint - The fentanyl concept sector experienced a decline of 1.68% as of the market close on November 17, with companies such as Enhua Pharmaceutical, Renfu Pharmaceutical, and Lingrui Pharmaceutical leading the losses [1] Market Performance - The fentanyl concept sector ranked among the top decliners, with a notable drop compared to other sectors such as military restructuring, which increased by 4.72% [1] - Other sectors that saw declines include cell immunotherapy (-1.87%), weight loss drugs (-1.87%), and innovative drugs (-1.72%) [1] Capital Flow - The fentanyl concept sector saw a net outflow of 153 million yuan, with five stocks experiencing significant capital outflows [1] - Renfu Pharmaceutical had the highest net outflow at 83.49 million yuan, followed by Lingrui Pharmaceutical (36.78 million yuan) and Enhua Pharmaceutical (24.86 million yuan) [1] - Conversely, the stocks with net inflows included Guoyao Co., Botao Bio, and Dongfang Bio, with net inflows of 2.91 million yuan, 849,400 yuan, and 285,900 yuan respectively [1] Individual Stock Performance - The top stocks in the fentanyl concept sector by net outflow include: - Renfu Pharmaceutical: -2.36% with a net outflow of 83.49 million yuan - Lingrui Pharmaceutical: -2.12% with a net outflow of 36.78 million yuan - Enhua Pharmaceutical: -2.93% with a net outflow of 24.86 million yuan [1] - In contrast, Guoyao Co. and Botao Bio showed slight positive movements with net inflows [1]

Core Insights - The fentanyl concept index declined by 0.31%, ranking among the top decliners in the concept sector, with notable declines in stocks such as Botao Bio, Oriental Bio, and Lingrui Pharmaceutical [1][2] - Conversely, three stocks within the sector saw price increases, with Renfu Pharmaceutical, Enhua Pharmaceutical, and China National Pharmaceutical Modern rising by 1.02%, 0.52%, and 0.19% respectively [1][2] Market Performance - The fentanyl concept sector experienced a net inflow of 0.22 billion yuan, despite five stocks facing net outflows, with Oriental Bio leading the outflow at 14.71 million yuan [2] - Other stocks with significant net outflows included China National Pharmaceutical Modern (10.27 million yuan), Wanfu Bio (7.15 million yuan), and Botao Bio (3.49 million yuan) [2] Stock Movements - The top gainers in the fentanyl concept included Renfu Pharmaceutical, China National Pharmaceutical, and Lingrui Pharmaceutical, with net inflows of 42.39 million yuan, 15.59 million yuan, and 2.54 million yuan respectively [2] - The stock performance of Oriental Bio showed a decline of 0.97% with a turnover rate of 1.75%, while Renfu Pharmaceutical had a gain of 1.02% with a turnover rate of 1.51% [2]

Group 1 - The company emphasizes the importance of addressing investor concerns by increasing cash dividends and establishing a three-year shareholder return plan starting in 2024 [2] - The company is committed to advancing its strategic development plan and steadily improving operational performance to enhance company value [2]

Core Viewpoint - The company emphasizes the protection of investor rights and has established a series of measures to enhance shareholder returns and stabilize investor expectations [1] Group 1 - The company has developed a "Market Value Management System" and a "Shareholder Return Plan" for the next three years (2025-2027) [1] - Since 2024, the company has steadily increased its cash dividend ratio [1] - The company is committed to the principle of "investor-centric" management to promote stable business development [1]